{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T13:42:46Z","timestamp":1774532566519,"version":"3.50.1"},"reference-count":7,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>We offer an illustrative case about estrogen receptor (ER) imaging (also known as 16\u03b1-[<jats:sup>18<\/jats:sup>F]fluoro-17\u03b2-estradiol ([<jats:sup>18<\/jats:sup>F]-FES) PET) and the detection of metastatic lesions in the dural region. We present a case of a woman with ER-positive metastatic breast cancer and high [<jats:sup>18<\/jats:sup>F]-FES uptake in the dural region on PET imaging, without associated clinical symptoms. These lesions were missed on [<jats:sup>18<\/jats:sup>F]-FDG PET because of physiological [<jats:sup>18<\/jats:sup>F]-FDG uptake in the brain. This case highlighted some difficulties in the interpretation of imaging of brain metastases and demonstrated the added value of [<jats:sup>18<\/jats:sup>F]-FES PET imaging. [<jats:sup>18<\/jats:sup>F]-FES PET could be used to prove the presence of ER-positive metastases in the brain.<\/jats:p>","DOI":"10.1097\/rlu.0000000000003382","type":"journal-article","created":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T20:02:20Z","timestamp":1605211340000},"page":"e165-e167","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["Detection of Dural Metastases Before the Onset of Clinical Symptoms by 16\u03b1-[18F]Fluoro-17\u03b2-Estradiol PET in a Patient With Estrogen Receptor\u2013Positive Breast Cancer"],"prefix":"10.1097","volume":"46","author":[{"given":"Jorianne","family":"Boers","sequence":"first","affiliation":[{"name":"Medical Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina P.","family":"Schr\u00f6der","sequence":"additional","affiliation":[{"name":"Medical Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geke A. P.","family":"Hospers","sequence":"additional","affiliation":[{"name":"Medical Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik F. J.","family":"de Vries","sequence":"additional","affiliation":[{"name":"Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andor W. J. M.","family":"Glaudemans","sequence":"additional","affiliation":[{"name":"Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,11,12]]},"reference":[{"key":"bib2-20250621","first-page":"11","article-title":"Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition","volume":"126","year":"2019","journal-title":"Eur J Cancer"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.2967\/jnumed.117.198846","article-title":"18F-fluoroestradiol tumor uptake is heterogeneous and influenced by site of metastasis in breast cancer patients","volume":"59","year":"2018","journal-title":"J Nucl Med"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S1470-2045(18)30936-7","article-title":"Diagnostic accuracy and safety of 16\u03b1-[ 18 F]fluoro-17\u03b2-oestradiol PET-CT for the assessment of oestrogen receptor status in recurrent or metastatic lesions in patients with breast cancer: a prospective cohort study","volume":"20","year":"2019","journal-title":"Lancet Oncol"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"182","DOI":"10.2967\/jnumed.111.092734","article-title":"PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma","volume":"53","year":"2012","journal-title":"J Nucl Med"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/RLU.0000000000001347","article-title":"Recommendations and technical aspects of 16\u03b1-[18F]Fluoro-17\u03b2-estradiol PET to image the estrogen receptor in vivo","volume":"41","year":"2016","journal-title":"Clin Nucl Med"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"e465","DOI":"10.1016\/S1470-2045(13)70292-4","article-title":"PET imaging of oestrogen receptors in patients with breast cancer","volume":"14","year":"2013","journal-title":"Lancet Oncol"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/RLU.0000000000001724","article-title":"18F-FES PET has added value in staging and therapy decision making in patients with disseminated lobular breast cancer","volume":"42","year":"2017","journal-title":"Clin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003382","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T21:03:53Z","timestamp":1750539833000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,12]]},"references-count":7,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000003382","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11,12]]}}}